CIRIUM
29.12.2021 14:02:52 CET | Business Wire | Press release
Cirium, the aviation analytics firm, today released its On-Time Performance Review 2021, the global standard for airline and airport operational performance. Cirium awarded Delta Air Lines with the Platinum Award, recognizing the Atlanta-based carrier as the world’s best performing airline of the year for Operational Excellence.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211228005093/en/
The new annual award is presented to an airline with outstanding performance considering the complexity of the airline’s operation, volume of flights, diversity of its network and other key operational factors. The Platinum Award is based on a proprietary algorithm that considers an array of parameters and provides an output to compare airlines on a one-to-one basis as far as possible to ensure fairness, accuracy, and integrity.
“It was another challenging year for the aviation industry, however 2021 was certainly better than 2020, marking the start of the recovery,” said Jeremy Bowen, CEO, Cirium. “Delta Air Lines stood out this year when you consider the carrier’s size, network, and passenger delay minutes, as well as the number of completed flights. It’s an outstanding effort and achievement during a difficult period. All Nippon Airlines (ANA) is recognized as the most on-time airline in the world. Delta, ANA and the regional winners are congratulated.”
Cirium’s 2021 On-Time Performance Review reflects the second half of the year when flight volumes returned. Airlines globally operated nearly 25 million flights, a 10% increase from 2020, but still down 36% compared to 2019.
The report reviews the top performing airlines and airports globally and in specific categories.
Global Airlines
All Nippon Airways (ANA) is named as the most on-time airline in the Global category with 95% of its flights on time. The carrier was followed closely by Japan Airlines (JAL) with 94.1% — reflecting the high standard set by Japanese aviation when it comes to on-time performance. In third place was Aeroflot (91%), followed by LATAM (88.7%) and Delta Air Lines (87.8%).
North America
Delta Air Lines takes home the award for most on-time North American airline with 87.7% of its flights arriving on time. The carrier topped Alaska Airlines (81.7%) and American Airlines (80.5%).
Europe
Spanish IAG carriers — Vueling (92.1%), Iberia Express (91.8%) and Iberia (90.3%) — took three of the top five spots in the European category. Notably, Vueling has expanded internationally in 2021 with 65% of its third quarter capacity dedicated to international flights.
Asia Pacific
In the Asia Pacific, leading Japanese airlines ANA and JAL rank at the top. Airlines that operate a flight schedule consisting mainly of international flights wherein a state of near hibernation in Asia. Those carriers with a sizeable domestic market have fared better. This year’s Top 10 in Asia-Pacific is dominated by airlines with a significant domestic operation.
Latin America
Copa Airlines, an airline that was close to a complete shutdown at the start of the pandemic, is making a strong recovery and operating its expanding flight schedules at a very high level of on-time performance. The carrier won the Latin America category with 90.3% of its flights on time, followed by Aerolineas Argentinas (89.2%) and Azul (88.9%).
Middle East and Africa
South African Low-Cost Carrier, Safair, outperforms in the Middle East and Africa category as 96.4% of its flights were on time. The airline did not feature in the On-Time Performance Review 2019, however has expanded its international services to Mauritius — a holiday destination for South Africans — with focused operations. Royal Jordanian (89%) and Emirates (86.7%) rounded out the performers in the region.
Low-Cost Carriers
Solaseed Air, also a Japanese domestic operator and ANA affiliate, tops the Low-Cost Carrier category with 97.9% of its flights on time in 2021. The airline flies a network of 14 routes and has very nimble operations.
Top Global Airports
The report also identifies the world’s leading airports in on-time performance and Tokyo’s international airport, Haneda Airport, ranks as the most on-time airport globally. In 2021, 95.6% of the airport’s flights departed on time.
Cirium’s on-time performance reporting for airlines and airports is the longest-standing of such analysis in the industry, going back 13 years. Cirium resumed reporting in June 2021, as flight volumes returned, with regular monthly updates that help gauge the industry’s performance in getting passengers from point A to point B, on time. Cirium’s on-time performance analysis is based on flight data from over 600 sources of real-time flight information. For an airline to be on time, their flights must arrive at the airport gate within 15 minutes of the scheduled arrival time.
Click here to download the complimentary On-Time Performance Review 2021.
Ends
About Cirium
Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.
For further information please follow Cirium updates on LinkedIn or Twitter or visit www.cirium.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211228005093/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
